INSANE: 35 - The Real Truth

COVID vax: Pregnant women left behind

Clinical trials of COVID vaccines excluded pregnant people, which left many wondering whether to get vaccinated

Salon · Mar 1, 2022

A South African company addresses vaccine supply inequity, despite Canada's lack of support

Since late 2020, the inequitable access across the globe to COVID-19 vaccines has been a glaring problem. But a remarkable achievement earlier this month offers hope that the supply of vaccines to developing countries will improve: Afrigen Biologics, a South African based company, produced its own version of Moderna’s mRNA…

The Conversation · Feb 28, 2022

Expert Ratings For Moderna

Within the last quarter, Moderna (NASDAQ:MRNA) has observed the following analyst ratings:

Benzinga · Feb 28, 2022

Check Out What Whales Are Doing With MRNA

Someone with a lot of money to spend has taken a bullish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga · Feb 25, 2022

Longer Waiting Period Between mRNA COVID-19 Doses May Cut Heart Inflammation Risk, CDC Suggests

The Centers for Disease Control and Prevention said that younger males should consider waiting longer between doses of Pfizer Inc's (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) and Moderna

Benzinga · Feb 25, 2022

Pan corona vax in the works: mRNA scientist Drew Weissman

HYDERABAD: At a time when there are fears of the emergence of new Covid-19 variants, American physician-scientist Dr Drew Weissman, who along with Dr Katalin Kariko worked on the mRNA vaccine platform that enabled Pfizer and Moderna to develop Covid-19 vaccines, said his lab was now working on a pan…

The Times of India · Feb 24, 2022

Moderna Rallies After Q4 Earnings: What 2 Analysts Have To Say About COVID-19 Stock

Moderna, Inc.

Benzinga · Feb 24, 2022

Will Moderna Be 'One Of The Most Valuable Healthcare Companies' In The World? Steve Weiss Believes So

Moderna Inc (NASDAQ: MRNA) is on the move Thursday following strong quarterly financial results. Short Hills Capital's Steve Weiss decided to pick up additional shares of the commercial-stage biotech company after the report.

Benzinga · Feb 24, 2022

Moderna Rallies After Earnings Print: Could A Technical Reversal Be In Sight?

Moderna Inc. (NASDAQ: MRNA) shares are trading after the company reported better-than-expected fourth-quarter EPS and sales results and announced a new $3 billion buyback.

Benzinga · Feb 24, 2022

What's Going On With Moderna Shares Today?

Moderna Inc (NASDAQ: MRNA) shares are trading higher by 9.7% at $149.11 after the company reported better-than-expected fourth-quarter EPS and sales results and announced a new $3 billion buyback.

Benzinga · Feb 24, 2022